Methylene blue is not toxic at low doses, but it becomes increasingly dangerous as the dose rises. At therapeutic levels (under 2 mg/kg of body weight), it is considered safe and is used in hospitals to treat certain poisoning emergencies. Above 7 mg/kg, serious adverse effects begin to appear. This dose-dependent flip from helpful to harmful is one of the most important things to understand about this compound.
The Dose Makes the Poison
Methylene blue follows what pharmacologists call a hormetic dose-response curve, meaning it has opposite effects at low and high doses. At low intravenous doses (0.5 to 2 mg/kg), it acts as an antioxidant and is the standard treatment for methemoglobinemia, a condition where the blood can’t carry oxygen properly. At high doses (above 10 mg/kg), it does the exact opposite: it generates oxidative stress and can actually cause the same condition it’s meant to treat, by directly damaging hemoglobin.
The gap between a helpful dose and a harmful one is relatively narrow. Adverse effects start showing up at around 7 mg/kg. By 15 mg/kg, the risk of hemolysis (destruction of red blood cells) rises significantly, especially in newborns. In animal studies, the lethal dose varies widely by species: roughly 1,250 mg/kg in rats given it intravenously, but only about 42 mg/kg in sheep. For cats, lethal effects began at around 41 mg/kg intravenously, with a transient spike in blood pressure, respiratory changes, and methemoglobinemia observed before death.
What Overdose Looks Like
At doses above the therapeutic range, methylene blue can cause nausea, vomiting, headache, dizziness, confusion, chest pain, shortness of breath, and high blood pressure. These effects are dose-dependent, meaning they get worse as the amount increases. At surgical doses of 5 to 10 mg/kg, which have sometimes been used during certain operations, patients have experienced prolonged disorientation, vertigo, and tremor in the postoperative period.
One distinctive and mostly harmless sign of any dose is that it turns your urine and stool blue or green. This discoloration can also mask clinical signs of cyanosis (the bluish skin color that signals low oxygen), which can complicate medical assessment.
Who Faces the Highest Risk
People With G6PD Deficiency
The most serious genetic risk factor is glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme shortage that affects roughly 400 million people worldwide, particularly those of African, Mediterranean, and Southeast Asian descent. In people with this deficiency, methylene blue cannot be properly converted into its active form inside the body. Without that conversion, the compound doesn’t work as intended and instead triggers severe hemolysis, the rapid breakdown of red blood cells. This can be fatal. G6PD deficiency is considered a contraindication for methylene blue use.
People Taking Serotonergic Medications
Methylene blue is a potent inhibitor of monoamine oxidase A (MAO-A), one of the key enzymes that breaks down serotonin in the brain. Its potency at blocking this enzyme is roughly 700 times greater than linezolid, an antibiotic already known to cause dangerous serotonin buildup. This means combining methylene blue with medications that increase serotonin can trigger serotonin syndrome, a potentially life-threatening condition involving agitation, high fever, muscle rigidity, and seizures.
The FDA has issued a safety communication stating that methylene blue should generally not be given to patients taking serotonergic drugs. The list of interacting medications is long and includes common antidepressants and psychiatric drugs across several classes: SSRIs like sertraline (Zoloft), fluoxetine (Prozac), and escitalopram (Lexapro); SNRIs like venlafaxine (Effexor) and duloxetine (Cymbalta); tricyclic antidepressants like amitriptyline and imipramine; MAO inhibitors like phenelzine (Nardil); and other psychiatric medications including trazodone, buspirone, mirtazapine, and bupropion. If you take any medication for depression, anxiety, or related conditions, this interaction is something to take seriously.
Newborns and Pregnant Women
Neonates are particularly vulnerable to hemolysis at doses above 15 mg/kg. Methylene blue also crosses the placenta, and its use during pregnancy has been associated with fetal harm, including intestinal abnormalities. It is generally avoided during pregnancy unless the benefit clearly outweighs the risk.
Common Side Effects at Safe Doses
Even within the therapeutic range, methylene blue is not side-effect-free. Patients receiving it intravenously commonly report a temporary burning sensation at the injection site, nausea, sweating, and the characteristic blue-green discoloration of urine, skin, and mucous membranes. These effects are generally mild and resolve as the body clears the drug. High blood pressure and a temporary increase in heart rate have also been reported with intravenous use.
Large oral doses can cause fever. Subcutaneous injection (under the skin rather than into a vein) can cause tissue death and abscesses at the injection site. Injection into the spinal canal has been linked to paralysis affecting all four limbs. These more severe effects are tied to specific routes of administration that are not part of standard treatment protocols.
The Bottom Line on Safety
Methylene blue sits in an unusual category: it is both a legitimate, FDA-recognized medication and a compound that can cause the very problems it treats if used improperly. Under 2 mg/kg intravenously, it is well-tolerated in most people. Between 2 and 7 mg/kg, side effects become more likely. Above 7 mg/kg, it becomes genuinely dangerous, and above 10 mg/kg, it flips into a pro-oxidant that damages blood cells and hemoglobin. For anyone with G6PD deficiency or taking serotonergic medications, even standard doses carry significant risk.